S100A8 (Protein | Antibody | cDNA Clone | ELISA Kit)

All S100A8 reagents are produced in house and quality controlled, including 15 S100A8 Antibody, 51 S100A8 Gene, 1 S100A8 IP Kit, 2 S100A8 Lysate, 4 S100A8 Protein, 2 S100A8 qPCR. All S100A8 reagents are ready to use.

S100A8 Protein (4)

    S100A8 Antibody (15)

      S100A8 cDNA Clone (51)


      S100A8 Lysate (2)

        More Product Popular With Customers

        S100A8 Background

        S1A8 is a member of the S1 protein family containing 2EF-hand calcium-binding motifs. S1 proteins are involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. Altered expression of S1A8 protein is associated with various diseases and cancers. S1A8 may have an immunoregulatory role by contributing to the regulation of fetal-maternal interactions. It may play a protective role and its absence may allow infiltration by maternal cells, a process eventually manifesting as resorption. The heterodimeric S1 protein complex S1A8/A9 which has been shown to be involved in inflammatory and neoplastic disorders. The complex can induce cell proliferation, or apoptosis, inflammation, collagen synthesis, and cell migration. S1A8/A9 has emerged as important pro-inflammatory mediator in acute and chronic inflammation. More recently, increased S1A8 and S1A9 levels were also detected in various human cancers, presenting abundant expression in neoplastic tumor cells as well as infiltrating immune cells. On the one hand, S1A8/A9 is a powerful apoptotic agent produced by immune cells, making it a very fascinating tool in the battle against cancer. It spears the risk to induce auto-immune response and may serve as a lead compound for cancer-selective therapeutics. In contrast, S1A8/A9 expression in cancer cells has also been associated with tumor development, cancer invasion or metastasis. Altogether, its expression and potential cytokine-like function in inflammation and in cancer suggests that S1A8/A9 may play a key role in inflammation-associated cancer.

        S100A8 References

        • Passey RJ, et al. (1999) S100A8: emerging functions and regulation. J Leukoc Biol. 66(4): 549-56.
        • Gebhardt C, et al. (2006) S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 72(11): 1622-31.
        • Halayko AJ, et al. (2009) S100A8/A9: a mediator of severe asthma pathogenesis and morbidity? Can J Physiol Pharmacol. 87(10): 743-55.
        • Ghavami S, et al. (2009) S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur J Pharmacol. 625(1-3): 73-83.
        • Ha YS, et al. (2010) mRNA Expression of S100A8 as a Prognostic Marker for Progression of Non-Muscle-Invasive Bladder Cancer. Korean J Urol. 51(1): 15-20.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.